Publicaciones (54) Publicaciones de JAVIER HORNEDO MUGUIRO

2023

  1. Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement

    eClinicalMedicine, Vol. 60

2020

  1. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

    Breast Cancer Research, Vol. 22, Núm. 1

  2. Impact of 68Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain

    Reports of Practical Oncology and Radiotherapy, Vol. 25, Núm. 3, pp. 405-411

2019

  1. Nintedanib plus letrozole in early breast cancer: A phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

    Breast Cancer Research, Vol. 21, Núm. 1

2018

  1. Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers

    Annals of Oncology, Vol. 29, pp. ix24

2009

  1. Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer

    Breast Journal

2008

  1. Factores pronósticos y predictivos

    Tratado de cáncer de mama (You & Us, S.A), pp. 13-24

  2. Novel chemotherapy approaches in chemoradiation protocols

    Gynecologic Oncology, Vol. 110, Núm. 3 SUPPL.2

2006

  1. Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: Efficacy and correlation with HER2 extracellular domain

    Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 896-902

  2. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support

    Journal of Clinical Oncology, Vol. 24, Núm. 22, pp. 3611-3618

  3. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia

    Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 889-895

2005

  1. Cancer-related anemia: Pathogenesis, prevalence and treatment

    Oncology

  2. It is not time to stop progesterone receptor testing in breast cancer [16]

    Journal of Clinical Oncology

2004

  1. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain

    Annals of Oncology, Vol. 15, Núm. 2, pp. 201-206

  2. Initially Metastatic Breast Carcinoma Has a Distinct Disease Pattern but an Equivalent Outcome Compared with Recurrent Metastatic Breast Carcinoma

    Cancer, Vol. 100, Núm. 9, pp. 1833-1842

  3. Massive thyroid tumoral embolism from a breast carcinoma presenting as acute thyroiditis

    Archives of Pathology and Laboratory Medicine, Vol. 128, Núm. 7, pp. 804-806

2003

  1. A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer

    Clinical Breast Cancer, Vol. 4, Núm. 4, pp. 286-291

  2. Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy

    Leukemia, Vol. 17, Núm. 2, pp. 437-441

  3. Principios de quimioterapia

    Oncología en atención primaria (Madrid: Nova sidonia oncología y hematología), pp. 99-106

2002

  1. Dynamic filters for the spectral analysis of random signals

    Measurement Techniques, Vol. 45, Núm. 5, pp. 544-551